These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22878826)

  • 1. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
    Ravandi F; Jorgensen JL
    J Natl Compr Canc Netw; 2012 Aug; 10(8):1029-36. PubMed ID: 22878826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Residual Disease in Acute Myeloid Leukemia.
    Gomez-Arteaga A; Guzman ML
    Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
    Freeman SD; Jovanovic JV; Grimwade D
    Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it time to routinely incorporate MRD into practice?
    Ravandi F
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRD in AML: it is time to change the definition of remission.
    Ossenkoppele GJ; Schuurhuis GJ
    Best Pract Res Clin Haematol; 2014; 27(3-4):265-71. PubMed ID: 25455276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
    Hokland P; Cotter F
    Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.
    Short NJ; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S25-9. PubMed ID: 27521321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
    Feng JH; Xu XJ; Tang YM
    Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
    Jorgensen JL; Chen SS
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
    Tomlinson B; Lazarus HM
    Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.